Controlled exposure
Retatrutide dosage in human trials
Published amounts describe supervised experiments. Retatrutide has no approved dosing, storage or reconstitution instructions for a non-trial preparation.
Published trial amounts
The trial amount has meaning together with the population, duration and supervision. I’m wary of dose lists that discard those details, because they make an experimental protocol look deceptively portable.
| Study | Amounts administered | Duration |
|---|---|---|
| Phase 1b, type 2 diabetes | 0.5, 1.5, 3 mg, with escalating groups | 12 weeks |
| Phase 2, obesity | 1, 4, 8, 12 mg | 48 weeks |
| Phase 2, type 2 diabetes | 0.5-12 mg | 36 weeks |
| Phase 2 liver-fat substudy | 1, 4, 8, 12 mg | 48 weeks |
These studies administered retatrutide once weekly by subcutaneous injection, into the fatty layer beneath the skin. The figures are descriptions of what the studies gave participants. They establish neither a personal dose nor a preparation standard for material obtained elsewhere.
Escalation and tolerability
Researchers increased amounts gradually in the clinical protocols to reduce gastrointestinal problems. In the obesity trial, larger amounts were associated with more gastrointestinal adverse events. The clinical protocol used gradual increases to manage tolerability. That design choice affects how the efficacy figures were reached.
I consider escalation part of the experiment worth understanding. A final trial amount tells only part of the exposure history. The starting amount, changes during follow-up and clinical monitoring all helped shape the experience that was recorded.
The phase 2 diabetes trial also used escalation. Its reported gastrointestinal events and glucose outcomes came from a monitored setting, with eligibility rules and staff follow-up.
Accumulation over time
The early human trial measured a half-life of approximately 6 days. A new administration therefore occurred while retatrutide from earlier administrations was still being cleared. Concentrations accumulated over about four to five weeks before levelling off.
I read early impressions cautiously while concentrations are still accumulating. A concentration measurement and a person’s symptoms describe different things.
Retatrutide reconstitution
There is no approved reconstitution standard for retatrutide outside clinical trials. Research-labelled powders have unverified identity, purity and sterility. The published human trials do not validate a home mixing method for those materials.
The same limitation applies to storage directions. A trial investigational product has manufacturing and handling controls that an online label cannot establish. No mixing, dilution or storage procedure appears here.
Retatrutide cost and availability
Retatrutide remains unapproved in the mid-2026 record. It has no approved pharmacy product or announced approved price. A price attached to research-labelled material says nothing reliable about its contents.
Access in this record is through clinical trials. The availability page covers the approval question; the side-effects account describes the clinical findings that sit alongside the trial amounts.